Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：13
|
作者：
Rimassa, Lorenza
Cicin, Irfan
Blanc, Jean-Frederic
Klumpen, Heinz Josef
Zagonel, Vittorina
Tran, Albert
Kim, Stefano Chong Hun
Lin, Zhong-Zhe
Tam, Vincent C.
Hazra, Saswati
Mangeshkar, Milan
El-Khoueiry, Anthony
Cheng, Ann-Lii
Meyer, Tim
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
机构：
[1] Humanitas Clin & Res Ctr, Rozzano, Italy
[2] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey
[3] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Oncol, Amsterdam, Netherlands
[5] Ist Oncol Veneto, IRCCS, Padua, Italy
[6] Grp Hosp Archet, Nice, France
[7] Univ Besancon, Ctr Hosp, Besancon, France
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Exelixis Inc, San Francisco, CA USA
[11] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Natl Taiwan Univ Hosp, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Association of Adverse Events (AES) with Efficiacy Outcomes for Cabozantinib (C) in Patients (PTS) with Advanced Hepatocellular Carcinoma (AHCC) in the Phase 3 Celestial Trial
    Waidmann, Oliver
    Abou-Alfa, G. K.
    Meker, T.
    Cheng, A. L.
    Cicin, I.
    Bolondi, L.
    Klumpem, H. J.
    Chan, S. L.
    Dadduzio, V.
    Milwee, S.
    Dubey, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [22] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [23] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
  • [24] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [25] Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    Cicin, Irfan
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Milwee, Steven
    Dubey, Sarita
    Kelley, Robin Kate
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Yau, T.
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y.
    Cicin, I.
    Harris, W. P.
    Banu, E.
    Sarker, D.
    Tan, B.
    van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Meyer, T.
    Cheng, A.
    Cicin, I.
    Bolondi, L.
    Klumpen, H.
    Chan, S.
    Zagonel, V.
    Milwee, S.
    Dubey, S.
    Kelley, R.
    El-Khoueiry, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 34
  • [30] Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
    Kelley, Robin Kate
    Meyer, Tim
    Rimassa, Lorenza
    Merle, Philippe
    Park, Joong-Won
    Yau, Thomas
    Chan, Stephen L.
    Blanc, Jean-Frederic
    Tam, Vincent C.
    Tran, Albert
    Dadduzio, Vincenzo
    Markby, David W.
    Kaldate, Rajesh
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4795 - 4804
12345